{
    "clinical_study": {
        "@rank": "161363", 
        "acronym": "03", 
        "arm_group": [
            {
                "arm_group_label": "Aplisol", 
                "arm_group_type": "Experimental", 
                "description": "To confirm the response of PPD materials"
            }, 
            {
                "arm_group_label": "PPD Standard", 
                "arm_group_type": "Active Comparator", 
                "description": "Determine equivalent specificity for new material compared to standard material."
            }
        ], 
        "brief_summary": {
            "textblock": "Determine if investigational products and reference standard produce similar responses."
        }, 
        "brief_title": "Equivalence Study of Specificity of PPD", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Tuberculosis Infection", 
        "condition_browse": {
            "mesh_term": "Tuberculosis"
        }, 
        "detailed_description": {
            "textblock": "Primary:\n\n      To determine if the 2 investigational products (Aplisol formulated from the new Tuberculin\n      PPD drug substance and the reference standard PPD-S2) produce qualitatively similar\n      responses (positive or negative) in subjects who are uninfected with M. tuberculosis (Mtb)\n      or other mycobacteria.\n\n      Secondary:\n\n        1. To determine if the 2 investigational products have equivalent specificity for\n           detecting subjects currently or previously infected with Mtb;\n\n        2. To assess the tolerability of the investigational products in terms of the local and\n           systemic reactogenicity events."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or nonpregnant females, age 18 to 70 years\n\n               -  Negligible risk of manifesting a positive PPD test as evidenced by:\n\n                    -  Prior history of negative PPD test or interferon gamma release assay (IGRA)\n                       within 14 months before Screening\n\n                    -  No history of Bacillus Calmette- Gu\u00e9rin vaccination; or if vaccination\n                       status is uncertain, was born in the US and did not live outside the US as\n                       a child\n\n                    -  No history of Mtb or Mtb therapy (including isoniazid, rifampin,\n                       ethambutol, pyrazinamide, or streptomycin)\n\n                    -  No history of infection with atypical mycobacteria, including suspicious\n                       chest roentgenogram\n\n                    -  No history of high risk medical conditions (eg, HIV infection or other\n                       immunosuppressive conditions, severe chronic renal disease [as evidenced by\n                       a creatinine clearance < 30 ml/min], poorly controlled diabetes mellitus,\n                       silicosis, intravenous drug use, or alcohol abuse)\n\n                    -  No known close contact to a confirmed Mtb case (family or social setting)\n\n                    -  No history of living or travelling in India, China, Sub-Saharan Africa, or\n                       Southeast Asia in the past 6 months\n\n                    -  No exposure (other than casual) to high-risk environments for Mtb exposure\n                       (eg, prisons, homeless shelters); healthcare workers are allowed\n\n        Exclusion Criteria:\n\n          -  Subject is of childbearing potential and unable to use contraceptives; is planning\n             pregnancy; is pregnant or lactating\n\n               -  History of anaphylactic type reaction or other severe reaction to PPD in the\n                  past, including a history of blistering or sloughing\n\n               -  Presence of conditions that may suppress TST reactivity, including:\n\n        Protocol No. JHP-Aplisol-03 Confidential 04 May 2012 Page 8 of 38\n\n          -  Acute viral infections, including measles, mumps, chicken pox, human immunodeficiency\n             virus (HIV1, HIV2). Mild viral syndromes are allowed.\n\n          -  Acute bacterial infections including typhoid fever, brucellosis, typhus, leprosy, or\n             pertussis\n\n          -  Acute systemic fungal infection\n\n          -  Live virus vaccinations within the past 6 weeks, including measles, mumps, polio,\n             varicella, or FluMist\u00ae\n\n          -  Metabolic derangements (eg, poorly controlled diabetes, Cushing syndrome, chronic\n             renal failure [as evidenced by a creatinine clearance < 30 ml/min])"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "152", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798095", 
            "org_study_id": "JHP-03"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Aplisol", 
                    "PPD Standard"
                ], 
                "description": "Determine equivalency of materials", 
                "intervention_name": "Aplisol@ PPD material", 
                "intervention_type": "Biological", 
                "other_name": "Aplisol@"
            }, 
            {
                "arm_group_label": [
                    "Aplisol", 
                    "PPD Standard"
                ], 
                "description": "Reference standard material for comparison to newly produced materials.", 
                "intervention_name": "Reference Standard", 
                "intervention_type": "Biological", 
                "other_name": "US Reference Standard"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "TB, Aplisol", 
        "lastchanged_date": "February 21, 2013", 
        "location": {
            "contact": {
                "email": "clin.res@uthct.edu", 
                "last_name": "Joe Santor, Pharm. D.", 
                "phone": "903-877-7632"
            }, 
            "facility": {
                "address": {
                    "city": "Tyler", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75708"
                }, 
                "name": "The University of Texas Health Science Center at Tyler"
            }, 
            "investigator": {
                "last_name": "David Griffith, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Equivalence Study of the Specificity of Tuberculin Purified Protein Derivative (PPD) (Aplisol\u00ae) in Comparison With a Reference Standard", 
        "overall_contact": {
            "last_name": "Arlene Lund, B.Sc.", 
            "phone": "919-985-3220"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine if the 2 investigational products (Aplisol formulated from the new Tuberculin PPD drug substance and the reference standard PPD-S2) produce qualitatively similar responses (positive or negative) in subjects who are uninfected with M. tuberculosis (Mtb) or other mycobacteria.Skin test responses will be used to determine product similarity in responses.", 
            "measure": "Determination of similarity in responses", 
            "safety_issue": "No", 
            "time_frame": "72 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798095"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To determine if the 2 investigational products have equivalent specificity for detecting subjects currently or previously infected with Mtb; 2) To assess the tolerability of the investigational products in terms of the localand systemic reactogenicity events. Skin responses to new PPD and reference standard will be monitored to determine equivalent specificity.", 
            "measure": "Determine equivalent specificity", 
            "safety_issue": "No", 
            "time_frame": "72 hours"
        }, 
        "source": "JHP Pharmaceuticals LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "INC Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "JHP Pharmaceuticals LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}